Alberto Farolfi

2.6k total citations
61 papers, 1.0k citations indexed

About

Alberto Farolfi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Alberto Farolfi has authored 61 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Alberto Farolfi's work include Ovarian cancer diagnosis and treatment (12 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Alberto Farolfi is often cited by papers focused on Ovarian cancer diagnosis and treatment (12 papers), HER2/EGFR in Cancer Research (9 papers) and Cancer Immunotherapy and Biomarkers (9 papers). Alberto Farolfi collaborates with scholars based in Italy, United States and United Kingdom. Alberto Farolfi's co-authors include Dino Amadori, Andrea Rocca, Ugo De Giorgi, Sara Bravaccini, Emanuela Scarpi, Alessio Schirone, Giuseppe Schepisi, Vincenza Conteduca, Cristian Lolli and Roberta Maltoni and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Free Radical Biology and Medicine.

In The Last Decade

Alberto Farolfi

57 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alberto Farolfi Italy	19	614	321	250	206	123	61	1.0k
Davide Lombardi Italy	17	609 1.0×	308 1.0×	210 0.8×	211 1.0×	80 0.7×	57	1.0k
Roberta Maltoni Italy	21	722 1.2×	299 0.9×	338 1.4×	376 1.8×	104 0.8×	84	1.2k
Yeşim Eralp Türkiye	21	555 0.9×	279 0.9×	186 0.7×	344 1.7×	103 0.8×	94	1.3k
Alexis Vallard France	18	357 0.6×	364 1.1×	324 1.3×	208 1.0×	108 0.9×	110	1.2k
Javier Gómez United States	18	361 0.6×	373 1.2×	270 1.1×	122 0.6×	116 0.9×	51	1.0k
Jurandyr Moreira de Andrade Brazil	21	690 1.1×	158 0.5×	317 1.3×	290 1.4×	274 2.2×	114	1.5k
Amy Tiersten United States	20	1.0k 1.7×	324 1.0×	264 1.1×	275 1.3×	211 1.7×	101	1.6k
Diane Savarese United States	16	576 0.9×	526 1.6×	274 1.1×	184 0.9×	101 0.8×	24	1.2k
Virginia E. Kwitkowski United States	16	423 0.7×	264 0.8×	484 1.9×	176 0.9×	81 0.7×	18	1.2k
Cristina Noberasco Italy	20	751 1.2×	337 1.0×	399 1.6×	374 1.8×	109 0.9×	75	1.5k

Countries citing papers authored by Alberto Farolfi

Since Specialization

Citations

This map shows the geographic impact of Alberto Farolfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Farolfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Farolfi more than expected).

Fields of papers citing papers by Alberto Farolfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alberto Farolfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Farolfi. The network helps show where Alberto Farolfi may publish in the future.

Co-authorship network of co-authors of Alberto Farolfi

This figure shows the co-authorship network connecting the top 25 collaborators of Alberto Farolfi. A scholar is included among the top collaborators of Alberto Farolfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alberto Farolfi. Alberto Farolfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Casadei, Chiara, Alberto Farolfi, Ernesto Paoletti, et al.. (2025). 86P Cardiovascular toxicities with first-line maintenance olaparib (ola) + bevacizumab (bev) in advanced ovarian cancer (aOC): A real-world analysis. ESMO Open. 10. 105215–105215.

Conteduca, Vincenza, Emanuela Scarpi, Alice S. Rossi, et al.. (2025). Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer. The Oncologist. 30(5). 1 indexed citations

Eminowicz, Gemma, Jérôme Alexandre, Elena Ioana Braicu, et al.. (2025). 1221TiP GOG-3119/ENGOT-en29/TroFuse-033: A phase III, randomized study of sacituzumab tirumotecan (sac-TMT) + pembrolizumab (pembro) vs pembro alone as first-line (1L) maintenance therapy for mismatch repair-proficient (pMMR) endometrial cancer (EC). Annals of Oncology. 36. S740–S740.

Gianni, Caterina, Alberto Farolfi, Michela Palleschi, et al.. (2025). Hormonal Therapy In Endometriosis And Breast Cancer Risk: A Propensity Score-Matched Real-World Analysis. International Journal of Gynecological Cancer. 35(2). 101267–101267. 1 indexed citations

Passarelli, Anna, Jole Ventriglia, Carmela Pisano, et al.. (2023). The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer. Frontiers in Oncology. 12. 1088962–1088962. 5 indexed citations

Farolfi, Alberto, Francesca Rusconi, Ilaria Massa, et al.. (2023). #434 Association between endometriosis and endometrial cancer: a real world evidence study. A35.2–A36. 1 indexed citations

Bartoletti, Michele, Alice Bergamini, Gaia Giannone, et al.. (2022). A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group. International Journal of Gynecological Cancer. 32(9). 1205–1207. 4 indexed citations

Conteduca, Vincenza, Chiara Casadei, Emanuela Scarpi, et al.. (2022). Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Cancers. 14(9). 2219–2219. 8 indexed citations

Schepisi, Giuseppe, Chiara Casadei, Alberto Farolfi, et al.. (2021). Immunotherapy and Its Development for Gynecological (Ovarian, Endometrial and Cervical) Tumors: From Immune Checkpoint Inhibitors to Chimeric Antigen Receptor (CAR)-T Cell Therapy. Cancers. 13(4). 840–840. 22 indexed citations

10.

Conteduca, Vincenza, Emanuela Scarpi, Paola Caroli, et al.. (2021). Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome. Molecular Oncology. 16(2). 538–548. 10 indexed citations

11.

Giannone, Gaia, Giulia Scotto, Dionyssios Katsaros, et al.. (2021). Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature. Gynecologic Oncology. 162(1). 80–87. 3 indexed citations

12.

Brighi, Nicole, Alberto Farolfi, Vincenza Conteduca, et al.. (2019). The Interplay between Inflammation, Anti-Angiogenic Agents, and Immune Checkpoint Inhibitors: Perspectives for Renal Cell Cancer Treatment. Cancers. 11(12). 1935–1935. 20 indexed citations

13.

Lolli, Cristian, Delia De Lisi, Vincenza Conteduca, et al.. (2019). Testosterone levels and androgen receptor copy number variations in castration‐resistant prostate cancer treated with abiraterone or enzalutamide. The Prostate. 79(11). 1211–1220. 16 indexed citations

14.

Conteduca, Vincenza, Giorgia Gurioli, Nicole Brighi, et al.. (2019). Plasma Androgen Receptor in Prostate Cancer. Cancers. 11(11). 1719–1719. 16 indexed citations

15.

Conteduca, Vincenza, Giorgia Gurioli, Lorena Rossi, et al.. (2018). Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer. BMC Cancer. 18(1). 1267–1267. 13 indexed citations

16.

Lisi, Delia De, Ugo De Giorgi, Cristian Lolli, et al.. (2018). Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?. Expert Opinion on Drug Metabolism & Toxicology. 14(4). 461–467. 9 indexed citations

17.

Schepisi, Giuseppe, Alberto Farolfi, Vincenza Conteduca, et al.. (2017). Immunotherapy for Prostate Cancer: Where We Are Headed. International Journal of Molecular Sciences. 18(12). 2627–2627. 37 indexed citations

18.

Farolfi, Alberto, Elisa Carretta, Angela Ragazzini, et al.. (2014). Does the time between CT scan and chemotherapy increase the risk of acute adverse reactions to iodinated contrast media in cancer patients?. BMC Cancer. 14(1). 792–792. 3 indexed citations

19.

Ibrahim, Toni, Alberto Farolfi, Emanuela Scarpi, et al.. (2012). Hormonal Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance between Primary Breast Cancer and Paired Metastases: Clinical Impact. Oncology. 84(3). 150–157. 48 indexed citations

20.

Farolfi, Alberto, Laura Ridolfi, Massimo Guidoboni, et al.. (2011). Liver Metastases from Melanoma: Hepatic Intra-Arterial Chemotherapy. A Retrospective Study. Journal of Chemotherapy. 23(5). 300–305. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact